Daiichi Sankyo Pays $39m To Settle U.S. Kickback Allegations
This article was originally published in PharmAsia News
The U.S. subsidiary of major Japanese company Daiichi Sankyo has agreed to pay a $39 million fine, plus fees and costs, to the U.S. Government and state Medicaid programs in a civil settlement to resolve allegations it paid kickbacks designed to induce physicians to prescribe certain of its drugs.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.